# 1. Financial Performance ## A. Key Figures * **Revenue:** ₹1,121 Cr Q2 FY'26 (highest in 10 quarters) (+7% YoY) · ₹1,045 Cr Q1 FY'26 * **EBITDA:** ₹146 Cr Q2 FY'26 (+8% YoY) · ₹300 Cr H1 FY'26 (+18% YoY) * PAT: ₹70 Cr Q2 FY'26 (+18% YoY) · ₹134 Cr H1 FY'26 (+34% YoY) * Net Debt/EBITDA: 1.24x TTM (Sep '25) | Net Debt: ₹748 Cr * **Capex:** ₹59 Cr Q2 FY'26 · ₹109 Cr YTD FY'26 | **FY'26 Guidance:** ~₹600 Cr ## B. Revenue Growth * **Record Top-Line Performance:** Highest quarterly revenue and volume in 10 quarters, driven by **high double-digit volume growth**, market share gains, and portfolio diversification. * **Resilient Demand:** Double-digit YoY and positive sequential revenue growth achieved despite global headwinds, reflecting strong execution and pricing discipline. ## C. EBITDA & Profit * **Profitability Expansion:** Robust PAT growth outpaced revenue, with **18% quarterly and 34% half-yearly increases**, supported by margin expansion in Specialty Chemicals. * **Cost Efficiency Momentum:** EBITDA growth driven by **ongoing lean savings (₹100 Cr+ annual program)** and **16% YoY decline in energy costs** from renewable shift and infrastructure upgrades. * **Sustainability Tailwinds:** Renewable energy share now **28%**, with O2 Power integration at Bharuch reducing power/fuel costs even amid higher production. ## D. Balance Sheet & Cash Flow * **Healthy Leverage Profile:** Net debt/EBITDA maintained at a manageable **2.4x**, with capex fully funded through internal accruals, preserving financial flexibility. * **Strategic Capex Deployment:** YTD spend of ₹109 Cr directed toward **CDMO Agro plant (Bharuch)** and **multipurpose facility (Gajraula)**, underpinning future growth capacity. --- # 2. Volume & Pricing Trends ## A. Key Figures * **Volume Growth:** **~18%** QoQ despite macro headwinds * **EBITDA Margin Guidance:** **20–25%** for key products * **ROCE Target:** **20%** minimum, consistent across segments * **Annual EBITDA from Large Contract:** **₹100–120 Cr** * **Power Cost Differential:** **₹5/unit** renewable vs. **₹7–9/unit** grid ## B. Segment Volumes * **Recovery Confirmed:** Global agrochemical volumes have stabilized and are now showing strong growth, marking exit from prior inventory destocking. * **Resilient Expansion:** Robust ~18% volume growth achieved despite muted pricing and macro challenges, signaling underlying demand strength. * **Near-Term Visibility:** Current quarter volumes expected to match prior quarter, with management targeting sustained performance. ## C. Price Momentum * **Choline Chloride Upside:** Realizations set to outperform domestic market due to reduced Chinese supply and favorable global dynamics. * **Niacinamide Rebound:** Pricing has stabilized post-trough with early signs of recovery; margin improvement expected if trend continues. * **Value-Grade Premium:** A **$2–3/ton pricing delta** exists between feed-grade and high-value grades, with materially higher margins on premium products. * **Contract Execution Confidence:** Pre-agreed pricing on major contract ensures **stable EBITDA delivery**; margins per business case expected from next quarter. * **Cost Optimization Runway:** Further fixed cost reductions and efficiency gains underway through improved operational norms. --- # 3. Product & Segment Performance ## A. Key Figures * **Specialty Chemicals Revenue:** **12% YoY growth** (Q2) * **Specialty Chemicals EBITDA:** **₹125 Cr** (+50% YoY), **26% margin** * **Chemical Intermediates Revenue:** **20% sequential growth**, **6% YoY growth** (Q2) * **Nutrition & Health Revenue:** **1% YoY decline** (Q2) * **Nutrition & Health EBITDA Margin:** **12%–14%** (Q2) ## B. Specialty Chemicals * **Robust Segment Profitability:** Specialty Chemicals delivered strong double-digit revenue growth and significant EBITDA expansion, driven by CDMO and Fine Chemicals momentum. * **CDMO Pipeline Strength:** Portfolio of new molecules expected to generate **~INR 1,200 Cr** in peak annual revenue, with **10+ opportunities** in advanced stages and early supply already underway. * **Margin Resilience Despite Volatility:** EBITDA margins held firm at 26% despite short-term headwinds from pyridine price fluctuations and planned plant maintenance. * **High-Grade Niacinamide Ramp-Up:** Human- and cosmetic-grade niacinamide production is scaling successfully, with rising mix expected to enhance **business stability and target margins of 16%–18%**. ## C. Nutrition & Health * **Volume Strength Offset by Pricing Pressure:** Record volumes in vitamin B3 and B4 contrasted with slight revenue decline, as feed-grade pricing volatility weighed on top-line growth. * **Strategic Shift to High-Value Grades:** Rising share of cosmetic, food, and pharma niacinamide is reducing exposure to volatile feed markets and supporting margin recovery toward **14%–15%**. * **European Choline Gains:** Strong traction with EU customers post anti-dumping duty, despite seasonal dip in choline volumes. ## D. Chemical Intermediates * **Record Sales Performance:** Segment achieved highest quarterly revenue and volumes in six quarters, led by strong demand for **Acetic Anhydride and Ethyl Acetate**. * **Derivatives Growth Momentum:** Pyridine and diketene derivatives delivered high double-digit growth, while Acetyl business showed volume recovery linked to domestic paracetamol and agrochemical demand. --- # 4. Capacity & Manufacturing ## A. Key Figures * **Niacinamide Production Increase:** **+25% to 30%** post-new plant ramp-up * **Renewable Power Contribution:** **28%** current, **35%** expected shortly * **Debottlenecking Gain:** **15% to 20%** capacity uplift in existing plants ## B. New Plants * **Strategic Expansion Underway:** Construction has begun on the Gajraula Manufacturing and Processing Plant, with a late 2026 completion target and production ramp-up expected in 2027. * **Multipurpose Capacity Advancing:** Groundbreaking completed for a new multipurpose plant at Gajraula, enhancing flexibility and scale for CDMO growth. * **Agro-Innovator Milestone Imminent:** The $300 million project remains on track for Q4 commissioning, reinforcing the company’s science-led, customer-centric CDMO strategy. * **Near-Term Volume Bridge:** Initial 2026 demand will be met via existing capacity while new facilities are commissioned. * **Recent CDMO Ramp-Up:** Commissioning of 10 new CDMO products reflects ongoing capability and capacity expansion. ## C. Debottlenecking * **Efficiency Enhancements in Progress:** A new boiler in Bharuch, set for Q3 FY’26 commissioning, supports a 15–20% debottlenecking across existing plants to capture incremental CDMO and fine chemical volumes. ## D. cGMP Facility * **Cosmetics Growth Accelerating:** The new cGMP facility is driving strong traction in the cosmetics segment, with rising customer interest and developed product pipeline. * **Human-Grade Vitamin B3 Live:** The vitamin B3 plant was commissioned in March, capable of producing both cosmetic-grade and human-grade niacinamide with operational flexibility. --- # 5. R&D & Innovation Pipeline ## A. Key Figures * **Peak Revenue Potential:** **INR3,500 Cr** total CDMO opportunity · **INR1,200 Cr** from confirmed deals * **CDMO Contract Value:** **$300 Mn** 5-year contract (~**$60 Mn/year**) · ~**INR500 Cr/year** run rate * **Pipeline Scale:** **50+ products** in development · **100+ opportunities** in pipeline ## B. CDMO Molecules * **Robust Deal Momentum:** Confirmed deals for over 10 molecules with peak revenue potential of INR1,200 Cr, including a major $300 Mn CDMO contract, with one molecule already shipped and revenue ramp-up expected next fiscal. * **Organizational Scaling:** R&D team expanded by nearly 20% and leadership strengthened to support accelerated CDMO and fine chemicals growth. * **High-Value Pipeline:** Strong double-digit growth in new molecule additions, with significant revenue contribution anticipated from differentiated, high-margin CDMO projects. ## C. Semiconductor Lab * **Strategic R&D Bet:** Establishment of a world-class semiconductor R&D lab in Greater Noida, focused on extreme cleanliness and advanced infrastructure, marks a long-term commitment to a 5–10 year innovation cycle. * **Global Traction & Investment:** Meaningful progress across 12+ molecules with customers in Europe, US, and Japan, backed by significant investments in high-cost equipment and dedicated facilities. ## D. Product Development * **Focused Launch Cadence:** Pipeline includes over 50 value-added products in development, with **18 new launches planned for FY '26** to capture emerging market demand. --- # 6. Customer & Geographic Mix ## A. Key Figures * **New CDMO Clients:** **10-plus** added over last three quarters * **Opportunity Funnel:** **Over 100** active prospects (up from 70 in Q1) * **Molecules in Pipeline:** **10 confirmed** secured · **10-plus additional** under discussion * **Strategic Molecules in Advanced Talks:** **6–8 Pharma** · **3–4 Agro** * **Major Contract Value:** **$300 million** exclusive supply agreement ## B. CDMO Clients * **New Client Momentum:** Robust addition of **10-plus new CDMO clients** over three quarters, reflecting strong market traction and expanded commercial reach. * **Growth Catalysts:** Major **$300 million contract** underway with initial Q2 deliveries; long-term growth expected to accelerate with upcoming **major CDMO order launch in early 2026**. * **Pipeline Depth:** Execution progressing on **10 confirmed molecules**, with **10-plus additional** in negotiation, signaling sustained revenue visibility across Pharma, Agro, Nutrition, and Cosmetics. * **Approval-Driven Upside:** **Higher volume orders and meaningful revenue uptick** anticipated upon completion of product approvals with **at least a dozen customers**. ## C. Export Markets * **Global Export Focus:** CDMO business is export-oriented, targeting **Europe, the US, and Japan**—with on-the-ground personnel now in place to strengthen engagement. ## D. Strategic Partnerships * **US Supply Chain Shift:** Strategic push supported by **US customers handholding the company**, driven by **de-risking from China** and establishing India as a resilient sourcing hub. * **Exclusive Commercial Model:** New product arrangements are predominantly **exclusive or semi-exclusive**, underpinned by **annual volume commitments**, enhancing revenue quality and customer stickiness. * **Leadership Expansion:** Recent hires of **Head of Nutrition and Health Ingredients** and **US Business Development Head** reinforce focus on innovation and geographic expansion. --- # 7. Pricing & Regulatory Risks ## A. Tariff Exposure * **Minimal Tariff Impact:** Only **2% of business** exposed to duties; company maintains competitive edge over Chinese suppliers post-tariff, resulting in **zero impact on existing operations**. * **Favorable Product Coverage:** No current or pipeline US-bound molecules are subject to tariffed chemical lists, supporting confidence in **limited future exposure**. * **Short-Term Deal Delays:** Tariff-related uncertainty has extended deal timelines from **3 to 6–8 months**, though long-term business impact remains negligible. ## B. EU Anti-Dumping * **Demand Uplift from EU Duty:** Anti-dumping measures on Chinese choline have generated a strong sales pipeline, with **early orders booked in Q2** and deliveries completed. * **Modest Revenue Contribution:** Despite positive momentum, revenue from anti-dumping-driven orders is **relatively small** within the broader Nutrition segment. ## C. Market Volatility * **Pricing Pressures Weigh on EBITDA:** Year-on-year EBITDA decline attributed to **market-driven contribution erosion**, driven by **subdued pricing** in an oversupplied environment with lower raw material costs. * **Temporary Softness in Key Segments:** **Pyridine, picoline**, and **Vitamin B3 derivatives** face near-term pricing softening, viewed as transitory based on historical feed price cycles. * **Acetyls Volatility Persists:** Pricing remains **highly volatile**, necessitating daily adjustments and precluding reliable forward-looking projections. --- # 8. Guidance & Outlook ## A. Key Figures * **Capex Commitment:** **INR2,000 Cr** total for CDMO and FC businesses ## B. Revenue Target * **Sustained Momentum:** Positive revenue momentum expected in H2 FY '26, supported by recovery across key segments and early contributions from 10 new molecules. * **Long-Term Growth Levers:** Revenue potential from a $800M–$1B intermediate market over 5–7 years and semi-conductor initiatives aligned with FY '30 goals. * **Guidance Unchanged:** Full financial outlook for FY '30 remains intact, including inorganic growth and partnership assumptions. ## C. Margin Projection * **Nutrition Margin Guidance:** 16%–18% target applies to the entire Nutrition segment, with recent margins near 15% despite under-penetrated higher-margin product lines. ## D. Capex Plan * **Fungible Capacity Strategy:** Multi-purpose plants enable flexible manufacturing across CDMO and FC businesses, optimizing capex efficiency. * **Cost Discipline:** Firm on track to deliver **INR100 Cr/year** savings via Lean 0, with additional opportunities expected from market dynamics and pricing pressures.